Drug intelligence / Profile preview

Fc-μTP-L309C

Development stage: Preclinical
Lead developer: CSL Behring
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intraperitoneal

Overview

Fc-μTP-L309C is a recombinant human IgG1 Fc hexamer with a point mutation at position 309 (L309C) fused to the human IgM tailpiece. It is designed to treat autoimmune diseases by inhibiting Fcγ receptor-mediated effector functions and the classical complement pathway. Fc-μTP-L309C has shown efficacy in models of arthritis and immune thrombocytopenia by reducing inflammatory cytokine production and complement activation at doses significantly lower than intravenous immunoglobulin (IVIG)[1][2][3].

Targets

C1Q (Complement C1q)FCGR3B (Low affinity immunoglobulin gamma Fc region receptor III-B)FCGR3B (Fc gamma receptor III)

Beyond the preview

Go deeper on Fc-μTP-L309C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fc-μTP-L309C.

Explore the full profile